{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"4.720","rs_stock_flag":false,"fiscal_year_end":"2025年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"838,892,874","primaryexch":"香港交易所","ric":"2592.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BT29C78","am":"1.87","iv":"","ew_strike":"","as":"4.610","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"4.580","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"4.530","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"Ni Jinsong","underlying_ric":"2592.HK","hi52":"9.740","issuer_name":"撥康視雲製藥有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"4.530","mkt_cap":"3.84","f_aum_hkd":null,"ew_sub_per_to":"","ls":"4.580","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.150","aum":"","issued_shares_class_B":null,"vo":"408.50","secondary_listing_flag":false,"listing_date":"2025年7月3日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"撥康視雲製藥有限公司 - B","nm_s":"撥康視雲－Ｂ","sym":"2592","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"Cloudbreak Pharma Inc是一家臨床階段的眼科生物技術公司，從事開發各種治療方法。該公司專注於眼科療法的內部發現、開發和商業化。該公司擁有兩款核心產品 CBT-001和CBT-009，均為自主研發。該公司的核心產品CBT-001用於治療翼狀胬肉（一種良性增生性眼表疾病），已在美國和中國啟動III期多區域臨床試驗（MRCT）。該公司的核心產品CBT-009用於治療青少年近視（5至19歲兒童和青少年的近視），已完成I/II期臨床試驗。該公司的其他候選藥物處於相對早期的開發階段，包括另外兩種臨床階段候選藥物，即CBT-006和CBT-004，以及四種臨床前階段候選藥物，即CBT-007、CBT-199、CBT-145和CBT-011。","op":"4.720","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港九龍<br/>海港城<br/>港威大廈2座<br/>23A樓23A11室","pc":"-3.17","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"4.730","isin":"KYG2215S1084","moneyness":""}},"qid":"1759074561404"}
